Form 4: MannKind EVP Thomson Granted Equity Incentives

MannKind Corp's EVP, General Counsel & Secretary, David Thomson, was granted 221,000 performance-based restricted stock units and 217,000 employee stock options.

Summary

• David Thomson, EVP, General Counsel & Secretary of MannKind Corp (MNKD), acquired 221,000 Performance Restricted Stock Units (RSUs) and 217,000 Employee Stock Options.
• The RSUs are performance-based, vesting on January 15, 2029, with the number of shares delivered dependent on MannKind's Total Shareholder Return (TSR) relative to the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026, to December 31, 2028.
• Payout for RSUs ranges from 0% to 300% of the target based on percentile ranking against the index (less than 25th percentile = 0%, 25th percentile = 50%, 50th percentile = 100%, 75th percentile = 200%, 90th percentile or higher = 300%).
• The Employee Stock Options have an exercise price of $2.44 per share.
• The stock options vest 25% on March 23, 2027, and then 1/16th quarterly thereafter, expiring on March 23, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns management incentives with long-term shareholder value through performance-based compensation.

Positives

• Grants align executive interests with shareholder value through performance-based vesting, encouraging long-term growth.
• The performance metrics for RSUs are tied to Total Shareholder Return (TSR) relative to an industry index, promoting competitive performance within the sector.
• The equity grants serve as a long-term incentive for a key executive, potentially enhancing retention and commitment.

Risks

• For the executive, the actual number of shares received from RSUs is contingent on MannKind's TSR performance relative to the Russell 3000 Pharmaceutical & Biotechnology Index, meaning the full target may not be achieved if performance is subpar.
• The value of the stock options is dependent on MannKind's stock price exceeding the $2.44 exercise price, posing a risk if the stock underperforms.

Future Outlook

The performance-based RSUs and stock options are designed to incentivize long-term performance, with vesting tied to future Total Shareholder Return relative to an industry index and a multi-year vesting schedule for options, indicating a focus on future value creation and strategic objectives.

Management Comments

• Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
• The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period.
• 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.

Industry Context

StockSavvy.ai notes that tying executive compensation to relative Total Shareholder Return (TSR) against a relevant industry index like the Russell 3000 Pharmaceutical & Biotechnology Index is a common practice in the biotech and pharmaceutical sectors. This approach aims to ensure that executive performance is measured not just by absolute growth but also by how the company performs compared to its peers, reflecting competitive market dynamics.

Comparison to Industry Standards

• The use of performance-based restricted stock units tied to relative TSR is a standard practice in executive compensation across many industries, particularly in biotech where long-term R&D cycles and market volatility are common.
• Comparing MannKind's TSR to the Russell 3000 Pharmaceutical & Biotechnology Index provides a relevant benchmark, as this index includes a broad range of companies within MannKind's operational sphere, similar to how larger pharmaceutical companies like Pfizer or Merck might benchmark against broader market indices.
• The vesting schedule for stock options (25% after one year, then quarterly) is also a typical structure designed to retain executives and incentivize sustained performance over several years, comparable to plans seen at companies like Amgen or Gilead Sciences.

Corporate Governance

Stakeholder Impact

• Shareholders: The performance-based nature of the grants aims to align executive incentives with shareholder value creation, potentially leading to improved long-term stock performance and accountability.
• Employees: The grants to a key executive may signal stability and a commitment to retaining top talent, which can positively impact overall employee morale and company direction.

Next Steps

• MannKind's Total Shareholder Return (TSR) will be measured against the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026, to December 31, 2028, to determine the final RSU payout.
• The granted employee stock options will begin vesting on March 23, 2027, with subsequent quarterly vesting.
• The performance-based restricted stock units will vest on January 15, 2029.

Key Dates

Keywords

MannKind Corp, MNKD, David Thomson, SEC Form 4, insider transaction, restricted stock units, stock options, executive compensation, performance-based equity, total shareholder return, Russell 3000 Pharmaceutical & Biotechnology Index